Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects (Q44438922)

3 December 2017

Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects (English)

1 reference

3 December 2017

1 reference

1 reference

https://api.crossref.org/works/10.1007/S00228-003-0565-7

1 January 2024

1 reference

2

Ulf Bredberg

1 reference

3 December 2017

Kristina Gislén

3

1 reference

3 December 2017

Lars Frison

5

1 reference

3 December 2017

Martin Ahnoff

6

1 reference

3 December 2017

David Gustafsson

7

1 reference

3 December 2017

Ulf G. Eriksson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12743672

1 January 2024

Linda C. Johansson

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12743672

1 January 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12743672

1 January 2024

publication date

27 March 2003

1 reference

full work available at URL

3 December 2017

http://link.springer.com/content/pdf/10.1007/s00228-003-0565-7.pdf

file format

Portable Document Format

1 reference

DOI

https://api.crossref.org/works/10.1007/S00228-003-0565-7

http://link.springer.com/article/10.1007/s00228-003-0565-7/fulltext.html

1 January 2024

1 reference

https://api.crossref.org/works/10.1007/S00228-003-0565-7

http://link.springer.com/content/pdf/10.1007/s00228-003-0565-7

1 January 2024

1 reference

DOI

https://api.crossref.org/works/10.1007/S00228-003-0565-7

European Journal of Clinical Pharmacology

1 January 2024

published in

1 reference

3 December 2017

59

1 reference

3 December 2017

1

1 reference

3 December 2017

35-43

1 reference

https://scigraph.springernature.com/pub.10.1007/s00228-003-0565-7

3 December 2017

0 references

cites work

Incidence and occurrence of total (first-ever and recurrent) stroke

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0565-7

Clinical epidemiology of acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0565-7

Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0565-7

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0565-7

Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0565-7

21 January 2018

New anticoagulant drugs

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0565-7

Prophylaxis of venous thromboembolism with subcutaneous melagatran in total hip or total knee replacement: results from Phase II studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0565-7

Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0565-7

The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0565-7

Determination of melagatran, a novel, direct thrombin inhibitor, in human plasma and urine by liquid chromatography-mass spectrometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0565-7

A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibiti

21 January 2018

1 reference

12 December 2020

Antithrombotic effect of two low molecular weight thrombin inhibitors and a low-molecular weight heparin in a caval vein thrombosis model in the rat

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT

1 reference

12 December 2020

Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat

1 reference

12 December 2020

Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes

1 reference

12 December 2020

Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery

1 reference

12 December 2020

The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis

1 reference

12 December 2020

The rationale for long-term prophylaxis of venous thromboembolism.

1 reference

12 December 2020

A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study.

1 reference

12 December 2020

Identifiers

DOI

1 reference

3 December 2017

1 reference